Your browser doesn't support javascript.
Risk of and duration of protection from SARS-CoV-2 reinfection assessed with real-world data.
Reynolds, Shannon L; Kaufman, Harvey W; Meyer, William A; Bush, Chris; Cohen, Oren; Cronin, Kathy; Kabelac, Carly; Leonard, Sandy; Anderson, Steve; Petkov, Valentina; Lowy, Douglas; Sharpless, Norman; Penberthy, Lynne.
  • Reynolds SL; Science and Delivery, Aetion, Inc., New York, New York, United States of America.
  • Kaufman HW; Medical Affairs, Quest Diagnostics, Secaucus, New Jersey, United States of America.
  • Meyer WA; Medical Affairs, Quest Diagnostics, Secaucus, New Jersey, United States of America.
  • Bush C; Science and Delivery, Aetion, Inc., New York, New York, United States of America.
  • Cohen O; Office of the Chief Medical Office, Labcorp Drug Development, Burlington, North Carolina, United States of America.
  • Cronin K; Division of Cancer Control and Population Science, National Cancer Institute, Bethesda, Maryland, United States of America.
  • Kabelac C; Science and Delivery, Aetion, Inc., New York, New York, United States of America.
  • Leonard S; Parternships and Real World Data, HealthVerity, Philadelphia, PA, United States of America.
  • Anderson S; Office of the Chief Medical Office, Labcorp Drug Development, Burlington, North Carolina, United States of America.
  • Petkov V; Division of Cancer Control and Population Science, National Cancer Institute, Bethesda, Maryland, United States of America.
  • Lowy D; Division of Cancer Control and Population Science, National Cancer Institute, Bethesda, Maryland, United States of America.
  • Sharpless N; Division of Cancer Control and Population Science, National Cancer Institute, Bethesda, Maryland, United States of America.
  • Penberthy L; Division of Cancer Control and Population Science, National Cancer Institute, Bethesda, Maryland, United States of America.
PLoS One ; 18(3): e0280584, 2023.
Article in English | MEDLINE | ID: covidwho-2278210
ABSTRACT
This retrospective observational study aimed to gain a better understanding of the protective duration of prior SARS-CoV-2 infection against reinfection. The objectives were two-fold to assess the durability of immunity to SARS-CoV-2 reinfection among initially unvaccinated individuals with previous SARS-CoV-2 infection, and to evaluate the crude SARS-CoV-2 reinfection rate and associated risk factors. During the pandemic era time period from February 29, 2020, through April 30, 2021, 144,678,382 individuals with SARS-CoV-2 molecular diagnostic or antibody test results were studied. Rates of reinfection among index-positive individuals were compared to rates of infection among index-negative individuals. Factors associated with reinfection were evaluated using multivariable logistic regression. For both objectives, the outcome was a subsequent positive molecular diagnostic test result. Consistent with prior findings, the risk of reinfection among index-positive individuals was 87% lower than the risk of infection among index-negative individuals. The duration of protection against reinfection was stable over the median 5 months and up to 1-year follow-up interval. Factors associated with an increased reinfection risk included older age, comorbid immunologic conditions, and living in congregate care settings; healthcare workers had a decreased reinfection risk. This large US population-based study suggests that infection induced immunity is durable for variants circulating pre-Delta predominance.
Subject(s)

Full text: Available Collection: International databases Database: MEDLINE Main subject: SARS-CoV-2 / COVID-19 Type of study: Cohort study / Experimental Studies / Observational study / Prognostic study Topics: Variants Limits: Humans Language: English Journal: PLoS One Journal subject: Science / Medicine Year: 2023 Document Type: Article Affiliation country: Journal.pone.0280584

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: SARS-CoV-2 / COVID-19 Type of study: Cohort study / Experimental Studies / Observational study / Prognostic study Topics: Variants Limits: Humans Language: English Journal: PLoS One Journal subject: Science / Medicine Year: 2023 Document Type: Article Affiliation country: Journal.pone.0280584